<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83269">
  <stage>Registered</stage>
  <submitdate>15/10/2008</submitdate>
  <approvaldate>29/10/2008</approvaldate>
  <actrnumber>ACTRN12608000546358</actrnumber>
  <trial_identification>
    <studytitle>Phase III-B, open randomized study to evaluate the coronary vasodilator effect of a generic or reference propatylnitrate formulation administrated in sublingual route during coronariography</studytitle>
    <scientifictitle>Phase III-B, open randomized study to evaluate the coronary vasodilator effect of a generic or reference propatylnitrate formulation administrated in sublingual route during coronariography</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Not aplicable</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>coronariography to investigate a coronary disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The study has 3 arms and are going to evaluate 2 doses of a propatylnitrate generic formulation (10mg and 20mg) comparing to a propatylnitrate reference formulation (10mg).

generic propatylnitrate 10mg administrated in sublingual route, 1 tablet during coronariography.

generic propatylnitrate 20mg administrated in sublingual route, 1 tablet during coronariography.

generic propatylnitrate means that the active drug is the same from reference propatylnitrate but it will be manufactured by other company. Since the propatylnitrate pharmacokinetics does not allow to calculate bioequivalence study it was decided together with Ministry of Helath to conduct a phase III-B study.</interventions>
    <comparator>reference propatylnitrate 10mg administrated in sublingual route, 1 tablet during coronariography.</comparator>
    <control>Active</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Vasodilator effect between a generic and a reference propatylnitrate formulation administrated in a sublingual route during coronariography. The coronariography will be performed by Judkins technic (femural access with manual injection of contrast non ionic low osmolarity named Henetix). The vasodilator effect will be measured by coronariographies images (30 images per second) and it will be recorded at a Philips Integris H500 machine (this tool is validated and described many times- Schnyder et al; Maier et al; Togni et al). The target segment to analise the drug vasodilator effect will be a 20mm segment defined by a anterior descending and circunflex arteries origin.</outcome>
      <timepoint>during coronariography</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Verify blood pressure during all coronariography phases to evaluate drug safety</outcome>
      <timepoint>during coronariography</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>subject who was clinical indicated to investigate coronary disease; 
subject who had not used a nitrate formulation or a calcium channel antagonist 12 hours before coronariography</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Acute miocardial infarction in less than 7 days; uncontrolled heart failure; cardiogenic arrest or haemodinamics instability; left coronary branch lesion &gt;50%, non protected; left ventricular ejection fraction &lt;30%; previous diagnosis of anterior decendent artery or cincurnflex occlusion; previous angioplasty with or without stent on the proximal third of the anterior decendent artery or on the circunflex; renal failure with creatinine &gt;1,8mg/dl or patient dojng peritoneal dyalises or hemodyalisis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>15/01/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eurofarma Laboratorios Ltda</primarysponsorname>
    <primarysponsoraddress>Av. Vereador Jos√© Diniz, 3465 - Sao Paulo</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Eurofarma Laboratorios Ltda</fundingname>
      <fundingaddress>Av. Vereador Jose Diniz, 3465 - Sao Paulo</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The intracoronary administration of 200 to 400 mcg of nitroglycerin is recommended before a cinecoronariography to prevent spontaneous or catheter induced spasms and to dilate the epicardic arteries and so optimize the quantification of coronary stenosis. When nitroglycerin is administrated intracoronaryly it enlarges the diameter of the coronary arteries in 10-20%, with minor enlargement in segments with major stenosis. The sublingual propatylnitrate, before the coronariography, can be an alternative to the intracoronary nitroglycerin. The main advantage of this alternative is the simplicity of the administration. However, there is no information about the coronary vasodilator effect of sublingual propatylnitrate.
The objective of this project is to compare the vasodilator effect of two formulations, the reference and the generics, of sublingual propatylnitrate during the coronariography.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Federal University of Sao Paulo</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tatiana Ferian da Fonseca</name>
      <address>Rua Borges Lagoa, 1080 - cj 101
Sao Paulo</address>
      <phone>55 11 5904 4454</phone>
      <fax />
      <email>tatiana@newcotrials.com</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Tatiana Ferian da Fonseca</name>
      <address>Rua Borges Lagoa, 1080 - cj 101
Sao Paulo</address>
      <phone>55 11 5904 4454</phone>
      <fax />
      <email>tatiana@newcotrials.com</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Tatiana Ferian da Fonseca</name>
      <address>Rua Borges Lagoa, 1080 - cj 101
Sao Paulo</address>
      <phone>55 11 5904 4454</phone>
      <fax />
      <email>tatiana@newcotrials.com</email>
      <country>Brazil</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>